CRO/Sponsor

Clinical Trial Supply Chain

Decentralized Clinical Trials

Early Phase Development

Investigative Sites

Protocol Design

Risk-Based Monitoring

Study Start-Up

Trial Design

Clinical Operations & Strategy

Diversity Action Plans

Industry Initiatives

Recruitment

Analytics

Electronic Data Capture

Metrics & Benchmarks

Real World Evidence

Data Management

CRAACO

Enrollment

Integrated Research

Patient Participation

Institutional Review Board & Ethics Committee

Regulatory

Artificial Intelligence/Machine Learning

eClinical

mHealth

Technology

News

Academy

Publications

All Publications

E-Books

Media

Editorial Podcasts

Editorial Videos

Peer Exchange

Practice Academy

Conferences

Conference Coverage

Conference Listing

Columns

All Columns

A Closing Thought

Clinical Trial Insights

View from Brussels

View from Washington

Resources

Advertise

Blogs

Events

Front & Center

Partner Perspectives

White Papers

Webcasts

Subscribe

Applied Clinical Trials is the thought leader in pharmaceutical drug development operations and clinical trial design, management, and monitoring.

About

Contact Us

Editorial Contacts

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Applied Clinical Trials Online

LinkedIN

Instagram

Facebook

Youtube

Soundcloud

Threads

Spotlight

DE&I

Topic

1rem

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in combination with Rituxan (rituximab) and Revlimid (lenalidomide) for relapsed or refractory follicular lymphoma demonstrated significant improvements in overall response rate and progression-free survival. 

Genmab’s Epkinly Shows Major Survival Benefit in Relapsed, Refractory Follicular Lymphoma

Results from the Phase III ATTAIN-1 trial (NCT05869903) showed that the highest dose of orforglipron achieved an average weight reduction of 12.4% in patients with obesity or overweight. 

Eli Lilly’s Investigational Oral GLP-1 Receptor Agonist Demonstrates Significant Weight Loss

The biotech company extends its Phase I trial (NCT06252220) of DA-1726 to eight weeks following encouraging early efficacy, safety, and weight loss data in patients with obesity.

MetaVia Expands GLP-1 Glucagon Receptor Agonist Obesity Trial Amid Signs of Superior Tolerability

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit over placebo in post-bunionectomy surgical pain relief. 

Vertex’s Selective NaV1.8 Inhibitor Falls Short in Acute Pain Clinical Trial

The FDA’s green light for a Phase II trial (JSKN003-202) of JSKN003 accelerates efforts to address platinum-resistant ovarian and related gynecologic cancers.

FDA Clears Alphamab’s Anti-HER2 Biparatopic Antibody-Drug Conjugate for Phase II Ovarian Cancer Trial

In this video interview, C.K. Wang, MD, chief medical officer, COTA, shares his key takeaways from a recent study he led on data reporting in oncology and highlights how stakeholders should be closely analyzing the accuracy of data they work with.

Ensuring Accuracy with Data in Oncology Research

, C.K. Wang, MD, chief medical officer, COTA, discussed a recent 

 he led on leveraging real-world data (RWD) to improve oncology reporting. Additionally, Wang highlighted recent trends and challenges in the oncology research space involving the use of RWD as well as real-world evidence (RWE).

ACT: What are your greatest takeaways from the study findings? How do you hope they impact the industry moving forward?

The takeaway from our study is that COTA’s composite mortality variable is very complete and very accurate. I would say that of the 21,500 records that we looked at across seven different cancers, and this includes acute myeloid leukemia, chronic lymphocytic leukemia, diffuse arch basil lymphoma, follicular lymphoma, marginal zone lymphoma, multiple myeloma, and myelodysplastic syndrome, we found our death data to carry a very high sensitivity and specificity at 87.8% and 95.7% as well as a very high positive predictive value and a very high negative predictive value as well at 90.9% and 94.1% respectively. I think, more importantly, what we found in our study is that mortality data, as documented in the medical record systems, on its own, has a relatively low sensitivity rate at 45.7%. Out of all this, it is my hope that our study findings will encourage everyone who's using real-world data to really scrutinize the completeness and the accuracy of the death data that they see, and for every provider of real-world data—whether it be another company, be a healthcare system, or oncology provider—to really step up to the plate and share the performance of their death information.

Videos

In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses a recent study he led on the validity of using real-world data for reporting mortality.

Leveraging RWD to Improve Reporting in Oncology

ACT: Could you give our audience an overview of the recent study you led on leveraging RWD to improve reporting in oncology?

To start, COTA is an oncology real-world data company, and our data is clinical and comes from the actual medical record systems for our provider partners, and over the past six years, we have built large, ready to use databases across both blood cancers and solid tumors. I will say that two foundational components to when one is looking to use any real-world data set is to understand, number one, whether or not it is actually accurate, whether that you know that the data that you see is actually accurate, but more importantly is to understand how complete that data is. As we all know, in clinical trials, especially in oncology, overall survival remains the gold standard by which any new therapy is actually being looked at. The completeness of the mortality data, whether it be in the clinical trials or in real-world data, remains extremely important. This is exactly what we set out to do in our study. We looked at, across all of our hematologic cancer databases, and we compare the accuracy and the completeness of our composite mortality variable against the national death index, which is the gold standard death database as we know it today.

Metrics & Benchmarks

Latest News